RESUMO
WHAT IS KNOWN AND OBJECTIVE: Stenotrophomonas maltophilia is an intrinsically multidrug-resistant (MDR) organism which commonly presents as a respiratory tract infection. S. maltophilia is typically treated with high-dose sulfamethoxazole/trimethoprim (SMX/TMP). However, SMX/TMP and other treatment options for S. maltophilia can be limited because of resistance, allergy, adverse events or unavailability of the drug; use of novel agents may be necessary to adequately treat this MDR infection and overcome these limitations. CASE DESCRIPTION: This small case series describes two patients who underwent treatment with tigecycline for ventilator-associated pneumonia (VAP) caused by S. maltophilia after admission to a trauma intensive care unit. At the time of admission for the two reported patients, a national drug shortage of intravenous (IV) SMX/TMP prevented its use. Tigecycline was chosen as a novel agent to treat S. maltophilia VAP based on culture and susceptibility data, and it was used successfully. Both patients showed clinical signs of improvement with eventual cure and discharge from the hospital after treatment with tigecycline, and one patient demonstrated confirmed microbiological cure with a negative repeat bronchoscopic bronchoalveolar lavage (BAL). WHAT IS NEW AND CONCLUSION: To our knowledge, this small case series is the first documentation of utilizing tigecycline to treat S. maltophilia VAP in the United States. Although it likely should not be considered as a first-line agent, tigecycline proved to be an effective treatment option in the two cases described in the setting of a national drug shortage of the drug of choice.
Assuntos
Antibacterianos/uso terapêutico , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Stenotrophomonas maltophilia/efeitos dos fármacos , Tigeciclina/uso terapêutico , Adulto , Humanos , Unidades de Terapia Intensiva , Masculino , Combinação Trimetoprima e Sulfametoxazol/provisão & distribuição , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Ferimentos e Lesões/terapiaRESUMO
BACKGROUND: Despite Namibia's robust medicine use systems and policies, antibiotic use indicators remain suboptimal. Recent medicine use surveys rank cotrimoxazole, amoxicillin and azithromycin (CAA) among the most used medicines. However, there is rising resistance to CAA (55.9%-96.7%). Unfortunately, to date, there have been limited studies evaluating policies to improve antibiotic use in Namibia. AIM: To evaluate public sector pharmaceutical policies and guidelines influencing the therapeutic use of CAA antibiotics in Namibia. METHODS: Evaluate Namibia's pharmaceutical policies and guidelines for CAA use through quantitative text analysis. The main outcome variables were the existence of antibiotic policies, therapeutic indications per antibiotic and the type/level of healthcare facility allowed to use the antibiotic. RESULTS: Policies for antibiotic use were limited, with only the draft Namibia Medicines Policy having a statement on antibiotic use. Several essential antibiotics had no therapeutic indications mentioned in the guidelines. Twenty-nine antibiotics were listed for 69 therapeutic indications; CAA (49.3%) antibiotics and ATC J01C/J01D (48%) having the highest indications per antibiotic. For CAA antibiotics, this suggested use was mainly for acute respiratory infections (n=22, 37.2%). Published policies (58.6%-17/29) recommended antibiotics for use at the primary healthcare (PHC) level, with CAA antibiotics recommended mostly for respiratory tract infections and genitourinary infections. CONCLUSIONS: Policy and guidelines for antibiotic use in Namibia are not comprehensive and are skewed towards PHCs. Existing policies promote the wide use of CAA antibiotics, which may inadvertently result in their inappropriate use enhancing resistance rates. This calls for the development of more comprehensive antibiotic guidelines and essential medicine lists in tandem with local antimicrobial resistance patterns. In addition, educational initiatives among all key stakeholder groups.
Assuntos
Antibacterianos/provisão & distribuição , Benchmarking , Serviços Comunitários de Farmácia/normas , Guias de Prática Clínica como Assunto , Padrões de Prática Médica/normas , Amoxicilina/provisão & distribuição , Azitromicina/provisão & distribuição , Quimioterapia Combinada , Humanos , Namíbia , Setor Público , Combinação Trimetoprima e Sulfametoxazol/provisão & distribuiçãoRESUMO
OBJECTIVE: To assess the quality of clinical care provided to patients with HIV in Felege Hiwot Referral Hospital. APPROACH AND DESIGN: Normative evaluation based on Donabedian's structure-process-outcome model of health care quality. Cross-sectional STUDY DESIGN: was employed to gather data in September 2007. SETTING: Felege Hiwot Referral Hospital is a government hospital in North West Ethiopia. The hospital is providing clinical care for patients infected with HIV free of patient charge since 2005. MEASURES: The evaluation used 10 process and 5 outcome indicators of quality measured by reviewing 351 randomly selected patient records and interview with 368 patients. Resource inventory was conducted to assess the availability of trained staff, laboratory facilities and drugs required for provision of HIV care. RESULTS: All resources recommended by the national antiretroviral therapy (ART) Implementation Guideline including trained staff, laboratory facilities and drugs were continuously available, except for a shortage of cotrimoxazole. Despite this, important components of care and treatment recommended by national treatment guidelines were not delivered for significant portion of patients. The study showed that only 45.9% of patients eligible for cotrimoxazole prophylactic therapy (CPT) and 76.8% of patients eligible for ART were actually taking CPT and ART, respectively. Compliance with national guidelines to monitor patients was also found to be a major problem. CONCLUSION: Availability of resources alone does not ensure the quality of HIV care and treatment. The study results indicate a need for regular monitoring and improvement of processes and outcomes of care in the Ethiopian Health System.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Avaliação de Processos e Resultados em Cuidados de Saúde/métodos , Adolescente , Fármacos Anti-HIV/provisão & distribuição , Antibioticoprofilaxia/normas , Criança , Pré-Escolar , Estudos Transversais , Etiópia , Feminino , Fidelidade a Diretrizes/estatística & dados numéricos , Infecções por HIV/prevenção & controle , Humanos , Lactente , Masculino , Satisfação do Paciente , Qualidade da Assistência à Saúde , Estavudina/provisão & distribuição , Estavudina/uso terapêutico , Combinação Trimetoprima e Sulfametoxazol/provisão & distribuição , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Adulto Jovem , Zidovudina/provisão & distribuição , Zidovudina/uso terapêuticoAssuntos
Anti-Infecciosos/provisão & distribuição , Infecções/tratamento farmacológico , Reposicionamento de Medicamentos , Substituição de Medicamentos , Foscarnet/provisão & distribuição , Foscarnet/uso terapêutico , Humanos , Meropeném , Tienamicinas/provisão & distribuição , Tienamicinas/uso terapêutico , Combinação Trimetoprima e Sulfametoxazol/provisão & distribuição , Combinação Trimetoprima e Sulfametoxazol/uso terapêuticoRESUMO
Antimicrobial shortages have made treating certain infections more difficult. A web-based survey asking about experience with antimicrobial drug shortages was distributed in 2011 to 1328 infectious diseases physician members of the Emerging Infectious Diseases Network of the Infectious Diseases Society of America. A majority (78%) of 627 respondents reported needing to modify antimicrobial choices because of drug shortages within the past 2 years. Antimicrobials most often reported as not available or available but in short supply were trimethoprim-sulfamethoxazole injection (by 65% of respondents), amikacin (by 58%), aztreonam (by 31%), and foscarnet (by 22%). Most respondents (55%) reporting a shortage indicated that the shortage adversely affected patient outcomes and that they were forced to use alternative and second line agents which were either less effective, more toxic, or more costly. Most (70%) indicated that they learned about the shortage from contact with the pharmacy after trying to prescribe a drug in short supply. More effective means of informing physicians about drug shortages is critical to lessen the impact on patient care.
Assuntos
Anti-Infecciosos/provisão & distribuição , Doenças Transmissíveis/tratamento farmacológico , Serviço de Farmácia Hospitalar/organização & administração , Amicacina/provisão & distribuição , Aztreonam/provisão & distribuição , Atenção à Saúde/organização & administração , Substituição de Medicamentos/efeitos adversos , Substituição de Medicamentos/economia , Foscarnet/provisão & distribuição , Pesquisas sobre Atenção à Saúde , Humanos , Médicos , Sociedades Médicas , Combinação Trimetoprima e Sulfametoxazol/provisão & distribuiçãoRESUMO
This paper reviews the data sources and methods used to estimate the number of people on, and coverage of, antiretroviral therapy (ART) programmes in low- and middle-income countries and to monitor the progress towards the "3 by 5" target set by WHO and UNAIDS. We include a review of the data sources used to estimate the coverage of ART programmes as well as the efforts made to avoid double counting and over-reporting. The methods used to estimate the number of people in need of ART are described and expanded with estimates of treatment needs for children, both for ART and for cotrimoxazole prophylaxis. An estimated 6.5 million people were in need of treatment in low- and middle-income countries by the end of 2004, including 660,000 children under age 15 years. The mid-2005 estimate of 970,000 people receiving ART in low- and middle-income countries (with an uncertainty range 840,000-1,100,000) corresponds to a coverage of 15% of people in need of treatment.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Adolescente , Fármacos Anti-HIV/provisão & distribuição , Quimioprevenção , Criança , Pré-Escolar , Coleta de Dados , Países em Desenvolvimento , Feminino , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Humanos , Lactente , Recém-Nascido , Masculino , Avaliação das Necessidades , Avaliação de Programas e Projetos de Saúde , Combinação Trimetoprima e Sulfametoxazol/provisão & distribuição , Nações Unidas , Organização Mundial da SaúdeRESUMO
OBJECTIVES: To characterize availability of fever and malaria medicines within the retail sector in rural Tanzania, assess the likely public health implications, and identify opportunities for policy interventions to increase the coverage of effective treatment. METHODS: A census of retailers selling drugs was undertaken in the areas under demographic surveillance in four Tanzanian districts, using a structured questionnaire. RESULTS: Drugs were stocked by two types of retailer: a large number of general retailers (n = 675) and a relatively small number of drug shops (n = 43). Almost all outlets stocked antipyretics/painkillers. One-third of general retailers stocking drugs had antimalarials, usually chloroquine alone. Almost all drug shops stocked antimalarials (98%): nearly all had chloroquine, 42% stocked quinine, 37% sulphadoxine-pyrimethamine and 30% amodiaquine. A large number of antimalarial brands were available. Population ratios indicate the relative accessibility of retail drug providers compared with health facilities. Drug shop staff generally travelled long distances to buy from drugs wholesalers or pharmacies. General retailers bought mainly from local general wholesalers, with a few general wholesalers accounting for a high proportion of all sources cited. CONCLUSIONS: Drugs were widely available from a large number of retail outlets. Potential negative implications include provision of ineffective drugs, confusion over brand names, uncontrolled use of antimalarials, and the availability of components of potential combination therapy regimens as monotherapies. On the other hand, this active and highly accessible retail market provides opportunities for improving the coverage of effective antimalarial treatment. Interventions targeted at all drug retailers are likely to be costly to deliver and difficult to sustain, but two promising points for targeted intervention are drug shops and selected general wholesalers. Retail quality may also be improved through consumer education, and modification of the chemical quality, packaging and price of products entering the retail distribution chain.